Novo nordisk a/s: mim8 demonstrated superior reductions in annualised bleeding rate (abr) compared to on-demand and prior prophylaxis treatment in people with haemophilia a

Frontier2 data presented at isth 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on mim8

NVO Ratings Summary

NVO Quant Ranking